Table 2.
Canonical Pathway Alterations Associated with EGFRvIII Expression: Canonical Pathways With Significant Differences in Expression Between EGFRvIII and non-EGFRvIII Samples
| Canonical pathway | Higher expression in | Z-score | Associated molecules |
|---|---|---|---|
| DNA methylation and transcriptional repression signaling | EGFRvIII samples | −2.236 | CDK12, CDK6, GATAD2A, H4C1, MTA1, ZEB1 |
| PPARα/RXRα activation | EGFRvIII samples | −2.236 | ACVR1, AIP, GUCY1B1, MAP2K4, PLCB1, RAP2A, RRAS2 |
| CLEAR signaling pathway | EGFRvIII samples | −1.667 | ATP6V1H, CREB5, EGFR, PPP3CB, RAP2A, RRAGA, RRAS2, TLR4, TSC2 |
| Ribonucleotide reductase signaling pathway | EGFRvIII samples | −1.342 | CDK6, CREB5, EGFR, MAP2K4, SMARCC1 |
| Epithelial adherens junction signaling | EGFRvIII samples | −1.134 | ACVR1, EGFR, NECTIN1, NOTCH1, NOTCH3, RAP2A, RRAS2 |
| cAMP-mediated signaling | EGFRvIII samples | −0.816 | CAMK2G, CREB5, GUCY1B1, PKIA, PKIG, PPP3CB, RGS10 |
| PTEN signaling | EGFRvIII samples | −0.447 | EGFR, FOXG1, INPPL1, RAP2A, RRAS2 |
| MicroRNA biogenesis signaling pathway | EGFRvIII samples | −0.378 | AGO2, DDX17, DICER1, EGFR, KHSRP, RAP2A, RRAS2 |
| PDGF signaling | non-EGFRvIII samples | 0.447 | ACP1, INPPL1, MAP2K4, RAP2A, RRAS2 |
| Superpathway of inositol phosphate compounds | non-EGFRvIII samples | 0.447 | ACP1, INPPL1, PLCB1, PPFIA1, PPP3CB, SSH2, STYXL1 |
| Dopamine-DARPP32 feedback in cAMP signaling | non-EGFRvIII samples | 0.447 | CREB5, CSNK1E, GUCY1B1, PLCB1, PPP3CB |
| Regulation Of The Epithelial-mesenchymal transition by growth factors pathway | non-EGFRvIII samples | 0.447 | EGFR, MAP2K4, RAP2A, RRAS2, ZEB1 |
| Pulmonary fibrosis idiopathic signaling pathway | non-EGFRvIII samples | 0.577 | ACVR1, CCN2, COL12A1, COL4A2, EGFR, FOXG1, JAG1, MAP2K4, NOTCH1, NOTCH3, RAP2A, RRAS2 |
| Estrogen receptor signaling | non-EGFRvIII samples | 0.707 | ATP5F1C, CREB5, EGFR, FOXG1, GUCY1B1, NOTCH1, PLCB1, RAP2A, RRAS2 |
| Autophagy | non-EGFRvIII samples | 0.816 | ATG5, CREB5, MAP2K4, PPP3CB, TLR4, TSC2 |
| Glioma signaling | non-EGFRvIII samples | 1 | CAMK2G, CCND3, CDK6, EGFR, HDAC6, IDH1, RAP2A, RRAS2 |
| Valine degradation I | non-EGFRvIII samples | 1 | ACADSB, BCAT1, ECHS1, HIBADH |
| UVC-induced MAPK signaling | non-EGFRvIII samples | 1 | EGFR, MAP2K4, RAP2A, RRAS2 |
| UVA-induced MAPK signaling | non-EGFRvIII samples | 1 | EGFR, MAP2K4, PLCB1, RAP2A, RRAS2 |
| D-myo-inositol-5-phosphate metabolism | non-EGFRvIII samples | 1 | ACP1, INPPL1, PLCB1, PPFIA1, PPP3CB, SSH2, STYXL1 |
| Endocannabinoid developing neuron pathway | non-EGFRvIII samples | 1 | CREB5, GUCY1B1, MAP2K4, RAP2A, RRAS2 |
| P2Y purigenic receptor signaling pathway | non-EGFRvIII samples | 1 | CREB5, GUCY1B1, PLCB1, RAP2A, RRAS2 |
| Paxillin signaling | non-EGFRvIII samples | 1 | ACTN2, MAP2K4, RAP2A, RRAS2 |
| NGF signaling | non-EGFRvIII samples | 1 | CREB5, MAP2K4, RAP2A, RRAS2 |
| STAT3 pathway | non-EGFRvIII samples | 1 | EGFR, MAP2K4, RAP2A, RRAS2 |
| GNRH signaling | non-EGFRvIII samples | 1.134 | CAMK2G, CREB5, EGFR, GUCY1B1, MAP2K4, PLCB1, RAP2A, RRAS2 |
| Wound healing signaling pathway | non-EGFRvIII samples | 1.134 | ACVR1, COL12A1, COL4A2, EGFR, MAP2K4, RAP2A, RRAS2 |
| Agrin interactions at neuromuscular junction | non-EGFRvIII samples | 1.342 | EGFR, ERBB4, MAP2K4, RAP2A, RRAS2 |
| Neurotrophin/TRK signaling | non-EGFRvIII samples | 1.342 | CREB5, MAP2K4, RAP2A, RRAS2, SPRY2 |
| Glioblastoma multiforme signaling | non-EGFRvIII samples | 1.342 | CCND3, CDK6, EGFR, PLCB1, RAP2A, RRAS2, TSC2 |
| ERBB signaling | non-EGFRvIII samples | 1.342 | EGFR, ERBB4, MAP2K4, RAP2A, RRAS2 |
| Insulin receptor signaling | non-EGFRvIII samples | 1.342 | GRB10, INPPL1, RAP2A, RRAS2, TRIP10, TSC2 |
| Neuregulin signaling | non-EGFRvIII samples | 1.342 | CDK5R1, EGFR, ERBB4, RAP2A, RRAS2 |
| Cholecystokinin/gastrin-mediated signaling | non-EGFRvIII samples | 1.342 | EGFR, MAP2K4, PLCB1, RAP2A, RRAS2 |
| Factors promoting cardiogenesis in vertebrates | non-EGFRvIII samples | 1.342 | ACVR1, CAMK2G, CREB5, MAP2K4, PLCB1 |
| Calcium signaling | non-EGFRvIII samples | 1.342 | CABIN1, CAMK2G, CREB5, HDAC6, PPP3CB, RAP2A |
| Thrombin signaling | non-EGFRvIII samples | 1.342 | CAMK2G, EGFR, GUCY1B1, PLCB1, RAP2A, RRAS2 |
| Opioid signaling pathway | non-EGFRvIII samples | 1.414 | CAMK2G, CREB5, GUCY1B1, MAP2K4, PLCB1, PPP3CB, RAP2A, RGS10, RRAS2 |
| Oxytocin signaling pathway | non-EGFRvIII samples | 1.414 | CREB5, EGFR, GUCY1B1, MAP2K4, PLCB1, PPP3CB, RAP2A, RRAS2 |
| Synaptic long-term potentiation | non-EGFRvIII samples | 1.633 | CAMK2G, CREB5, PLCB1, PPP3CB, RAP2A, RRAS2 |
| HIF1α signaling | non-EGFRvIII samples | 1.633 | CAMK2G, ELOC, MAP2K4, PPP3CB, RAP2A, RRAS2 |
| Role of osteoclasts in rheumatoid arthritis signaling pathway | non-EGFRvIII samples | 1.667 | COL12A1, COL4A2, CREB5, FOXG1, MAP2K4, PPP3CB, RAP2A, RRAS2, TLR4 |
| Chemokine signaling | non-EGFRvIII samples | 2 | CAMK2G, PLCB1, RAP2A, RRAS2 |
| LPS-stimulated MAPK signaling | non-EGFRvIII samples | 2 | MAP2K4, RAP2A, RRAS2, TLR4 |
| Apelin endothelial signaling pathway | non-EGFRvIII samples | 2 | GUCY1B1, MAP2K4, PLCB1, RAP2A, RRAS2 |
| TGF-β signaling | non-EGFRvIII samples | 2 | ACVR1, MAP2K4, RAP2A, RRAS2 |
| Oxidative phosphorylation | non-EGFRvIII samples | 2 | ATP5F1C, ATPAF1, COX7A2L, UQCRH |
| HMGB1 signaling | non-EGFRvIII samples | 2 | HAT1, MAP2K4, RAP2A, RRAS2, TLR4 |
| CXCR4 signaling | non-EGFRvIII samples | 2 | GUCY1B1, MAP2K4, PLCB1, RAP2A, RRAS2 |
| Role of MAPK signaling in promoting the pathogenesis of influenza | non-EGFRvIII samples | 2 | ATP6V1H, MAP2K4, RAP2A, RRAS2 |
| Fc epsilon RI signaling | non-EGFRvIII samples | 2 | INPPL1, MAP2K4, RAP2A, RRAS2 |
| fMLP signaling in neutrophils | non-EGFRvIII samples | 2 | PLCB1, PPP3CB, RAP2A, RRAS2 |
| Hepatic fibrosis signaling pathway | non-EGFRvIII samples | 2.121 | ACVR1, BRD4, CCN2, CREB5, CSNK1E, MAP2K4, RAP2A, RRAS2, TLR4 |
| 14-3-3-mediated signaling | non-EGFRvIII samples | 2.236 | MAP2K4, PLCB1, RAP2A, RRAS2, TSC2, TUBA4A |
| Ferroptosis signaling pathway | non-EGFRvIII samples | 2.236 | H2BC10, H2BC15, H2BC5, RAP2A, RRAS2 |
| Adipogenesis pathway | non-EGFRvIII samples | 2.236 | ACVR1, ATG5, HAT1, HDAC6, SOX9 |
| Cardiac hypertrophy signaling | non-EGFRvIII samples | 2.236 | GUCY1B1, MAP2K4, PLCB1, PPP3CB, RAP2A, RRAS2 |
| Senescence pathway | non-EGFRvIII samples | 2.449 | ACVR1, CCND3, CDK6, MAP2K4, PPP3CB, RAP2A, RRAS2 |
| Role of NFAT in cardiac hypertrophy | non-EGFRvIII samples | 2.646 | CABIN1, CAMK2G, GUCY1B1, HDAC6, MAP2K4, PLCB1, PPP3CB, RAP2A, RRAS2 |
| Cardiac Hypertrophy Signaling (enhanced) | non-EGFRvIII samples | 3 | ACVR1, CAMK2G, GUCY1B1, HDAC6, MAP2K4, PLCB1, PPP3CB, RAP2A, RRAS2, TSC2 |